Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialize axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,